What's Happening?
Invivoscribe has introduced the PrepQuant sample preparation platform, which integrates nucleic acid extraction, concentration, and quantification into a single automated system. Developed in collaboration with Hitachi High-Tech Corporation, PrepQuant aims
to standardize sample preparation and simplify pre-analytical workflows, reducing costs and inconsistencies in molecular testing. The system is assay agnostic, producing concentrated genomic DNA and cell-free DNA for various assays, including next-generation sequencing and digital PCR. By consolidating multiple steps, PrepQuant optimizes test results and operational efficiency. The platform is validated for use with blood, plasma, and bone marrow specimens, with plans to expand to other specimen types. Invivoscribe will unveil PrepQuant at the American Association for Cancer Research Annual Meeting.
Why It's Important?
The launch of PrepQuant represents a significant advancement in molecular testing, particularly in the era of precision medicine. By standardizing pre-analytical workflows, the platform addresses a major source of variability in test results, enhancing the reliability of measurable residual disease and liquid biopsy outcomes. This innovation is crucial for laboratories seeking to improve efficiency and reduce costs, as it minimizes the labor-intensive nature of current sample preparation methods. The collaboration between Invivoscribe and Hitachi High-Tech highlights the importance of technological partnerships in driving advancements in healthcare. As precision medicine continues to evolve, tools like PrepQuant will play a vital role in ensuring consistent and accurate diagnostic results.
What's Next?
Invivoscribe plans to expand the PrepQuant platform's capabilities to accommodate additional specimen types, further broadening its application in molecular testing. The official unveiling at the AACR Annual Meeting will provide an opportunity for industry professionals to explore the platform's features and potential benefits. As the demand for precision medicine grows, Invivoscribe's focus on standardization and efficiency may lead to increased adoption of PrepQuant in clinical laboratories worldwide. The company's ongoing development efforts will likely include enhancements to the platform's automation and integration capabilities, ensuring it remains at the forefront of molecular testing technology.
